Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer
Science Advances · 2023-11-24 · 9 (47)
DOI: 10.1126/sciadv.adj0123 ↗At a glance
Journal article in Science Advances, published on 2023-11-24. Written by Peiye Shen and 19 co-authors. Institution: State Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Ji…. Major MEDLINE topics: Neoplasm Recurrence, Local, Ovarian Neoplasms. Cited 28 times so far (Crossref); 87 references. The full text is freely available in PubMed Central.
Abstract (original language)
Transcriptional dysregulation is a recurring pathogenic hallmark and an emerging therapeutic vulnerability in ovarian cancer. Here, we demonstrated that ovarian cancer exhibited a unique dependency on the regulatory machinery of transcriptional termination, particularly, cleavage and polyadenylation specificity factor (CPSF) complex. Genetic abrogation of multiple CPSF subunits substantially hampered neoplastic cell viability, and we presented evidence that their indispensable roles converged on the endonuclease CPSF3. Mechanistically, CPSF perturbation resulted in lengthened 3′-untranslated regions, diminished intronic polyadenylation and widespread transcriptional readthrough, and consequently suppressed oncogenic pathways. Furthermore, we reported the development of specific CPSF3 inhibitors building upon the benzoxaborole scaffold, which exerted potent antitumor activity. Notably, CPSF3 blockade effectively exacerbated genomic instability by down-regulating DNA damage repair genes and thus acted in synergy with poly(adenosine 5'-diphosphate–ribose) polymerase inhibition. These findings establish CPSF3-dependent transcriptional termination as an exploitable driving mechanism of ovarian cancer and provide a promising class of boron-containing compounds for targeting transcription-addicted human malignancies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- State Key Laboratory of Systems Medicine for Cancer, Department of Obstetrics and Gynecology, Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Gynecologic Oncology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
ORCID profiles: Peiye Shen, Kaiyan Ye, Huaijiang Xiang, Zhenfeng Zhang, Qinyang He, Xiao Zhang, Mei-Chun Cai, Junfei Chen, Yunheng Sun, Lifeng Lin, Chunting Qi, Meiying Zhang, Lydia W T Cheung, Tingyan Shi, Xia Yin, Ying Li, Wen Di, Rongyu Zang, Li Tan, Guanglei Zhuang
Cite
APA
Shen, P., Ye, K., Xiang, H., Zhang, Z., He, Q., Zhang, X., Cai, M. C., Chen, J., Sun, Y., Lin, L., Qi, C., Zhang, M., Cheung, L. W. T., Shi, T., Yin, X., Li, Y., Di, W., Zang, R., Tan, L., & Zhuang, G. (2023). Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer. Science Advances, 9(47). https://doi.org/10.1126/sciadv.adj0123
Vancouver
Shen P, Ye K, Xiang H, Zhang Z, He Q, Zhang X, et al. Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer. Science Advances. 2023;9(47). doi:10.1126/sciadv.adj0123
BibTeX
@article{Shen2023,
author = {Shen, Peiye and Ye, Kaiyan and Xiang, Huaijiang and Zhang, Zhenfeng and He, Qinyang and Zhang, Xiao and Cai, Mei-Chun and Chen, Junfei and Sun, Yunheng and Lin, Lifeng and Qi, Chunting and Zhang, Meiying and Cheung, Lydia W T and Shi, Tingyan and Yin, Xia and Li, Ying and Di, Wen and Zang, Rongyu and Tan, Li and Zhuang, Guanglei},
title = {Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {47},
doi = {10.1126/sciadv.adj0123}
}
EUVIMED